In this practical session, Jake Walton, VP of Quality & Compliance at MasterControl, will share a candid look at how MasterControl approached AI the right way from the start—building human-in-the-loop...
A contamination control strategy (CCS) is usually treated as a document with sixteen elements assembled, signed, and shelved. This webinar offers a new perspective of a CCS as a machine...
Successfully scaling a purification process from development to GMP manufacturing requires maintaining process performance while minimizing variability. However, scale-up often introduces challenges that can impact productivity, recovery, and overall process...
Across biopharma operations, reactive “run‑to‑failure” maintenance is one of the biggest hidden drivers of downtime, deviations, and escalating lifecycle cost. As the industry moves toward digital maturity, organizations are shifting...
The key to unlocking maximum OEE? Integrating dosing accuracy, platen sealing, magnetic shuttle transport, and automated 100% in-line quality control into a unified workflow. Join our virtual event, "How to...
Mesenchymal stromal cell (MSC) therapies are entering a pivotal stage of development. As more programs move toward late-stage clinical trials and commercialization, developers must produce enough high-quality cells to meet...
Lipid nanoparticles (LNPs) are critical to the delivery of genetic medicines, but developing scalable, reproducible manufacturing processes remains complex and resource-intensive. Because LNP quality can be highly sensitive to formulation...
Strategies for supply assurance, QC readiness, digital optimization, and commercial bioprocessing success. The translation of cell culture processes from laboratory-scale development to commercial manufacturing remains one of the most critical...
Join us for an exclusive webinar exploring practical strategies to improve therapeutic antibody manufacturing through integrated upstream and downstream process solutions. As therapeutic antibody titers continue to rise, manufacturers face...
As the December 1, 2026 release of the revised USP <87>, Biological Reactivity Tests, In Vitro, approaches, pharmaceutical and medical device manufacturers should begin evaluating how these changes may impact...
